Advertisement
New Zealand markets close in 23 minutes
  • NZX 50

    11,793.40
    +61.12 (+0.52%)
     
  • NZD/USD

    0.6122
    +0.0025 (+0.42%)
     
  • NZD/EUR

    0.5650
    +0.0023 (+0.40%)
     
  • ALL ORDS

    8,083.10
    -35.20 (-0.43%)
     
  • ASX 200

    7,810.50
    -37.60 (-0.48%)
     
  • OIL

    77.04
    -0.53 (-0.68%)
     
  • GOLD

    2,374.40
    -18.50 (-0.77%)
     
  • NASDAQ

    18,705.20
    -8.59 (-0.05%)
     
  • FTSE

    8,370.33
    -46.12 (-0.55%)
     
  • Dow Jones

    39,671.04
    -201.95 (-0.51%)
     
  • DAX

    18,680.20
    -46.56 (-0.25%)
     
  • Hang Seng

    18,930.02
    -265.58 (-1.38%)
     
  • NIKKEI 225

    39,068.33
    +451.23 (+1.17%)
     
  • NZD/JPY

    95.9100
    +0.4070 (+0.43%)
     

A Struggling Pfizer Looks for Help From a Wall Streeter

A Struggling Pfizer Looks for Help From a Wall Streeter

As the big drugmaker tries to turn its fortunes around by focusing on oncology, it has turned to a Citi analyst who hasn’t recommended the stock in over a decade. But Andrew Baum has something Pfizer needs: oncology expertise.